1. Home
  2. EEX vs GERN Comparison

EEX vs GERN Comparison

Compare EEX & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EEX
  • GERN
  • Stock Information
  • Founded
  • EEX 2013
  • GERN 1990
  • Country
  • EEX United States
  • GERN United States
  • Employees
  • EEX N/A
  • GERN N/A
  • Industry
  • EEX Advertising
  • GERN Biotechnology: Pharmaceutical Preparations
  • Sector
  • EEX Consumer Discretionary
  • GERN Health Care
  • Exchange
  • EEX Nasdaq
  • GERN Nasdaq
  • Market Cap
  • EEX 910.8M
  • GERN 853.5M
  • IPO Year
  • EEX 2017
  • GERN 1996
  • Fundamental
  • Price
  • EEX $4.90
  • GERN $1.49
  • Analyst Decision
  • EEX Strong Buy
  • GERN Buy
  • Analyst Count
  • EEX 2
  • GERN 7
  • Target Price
  • EEX $7.90
  • GERN $4.17
  • AVG Volume (30 Days)
  • EEX 116.6K
  • GERN 10.4M
  • Earning Date
  • EEX 08-06-2025
  • GERN 08-07-2025
  • Dividend Yield
  • EEX 1.22%
  • GERN N/A
  • EPS Growth
  • EEX N/A
  • GERN N/A
  • EPS
  • EEX 0.02
  • GERN N/A
  • Revenue
  • EEX $413,100,000.00
  • GERN $116,293,000.00
  • Revenue This Year
  • EEX $14.85
  • GERN $160.12
  • Revenue Next Year
  • EEX $6.42
  • GERN $55.01
  • P/E Ratio
  • EEX $199.52
  • GERN N/A
  • Revenue Growth
  • EEX 4.87
  • GERN 22264.04
  • 52 Week Low
  • EEX $3.22
  • GERN $1.17
  • 52 Week High
  • EEX $6.74
  • GERN $5.06
  • Technical
  • Relative Strength Index (RSI)
  • EEX 59.77
  • GERN 51.44
  • Support Level
  • EEX $4.82
  • GERN $1.42
  • Resistance Level
  • EEX $4.93
  • GERN $1.57
  • Average True Range (ATR)
  • EEX 0.12
  • GERN 0.09
  • MACD
  • EEX -0.01
  • GERN -0.01
  • Stochastic Oscillator
  • EEX 65.89
  • GERN 35.19

About EEX Emerald Holding Inc.

Emerald Holding Inc is a business-to-business (B2B) event organizer principally in the United States. The company is engaged in three complementary business lines; Connections division consists of a collection of B2B trade show franchises and other live events that provide exhibitors opportunities to engage with buyers and expand their brand's awareness in their industry; the Content division consists of B2B print publications and digital media products that complement existing trade show properties, and the Commerce division which offers software-as-a-service technology that enables year-round B2B buying and selling through Elastic Suite and Bulletin platforms for use by its customers. The Majority of the revenue for the company is generated from its Connections segment.

About GERN Geron Corporation

Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.

Share on Social Networks: